Published Date: 26 Apr 2023
One million Americans currently have Parkinson's disease, and another 90,000 are diagnosed with it each year. It is currently the second most prevalent neurodegenerative disease in the country. And it's moving up to No. 1. However, few people are familiar with Parkinson's.
Read Full NewsProposed federal student loan caps will drive students into pricier private loans, or derail their aspirations of becoming PAs, creating professional healthcare shortages.
The U.S. Food and Drug Administration on Friday approved a new formulation of Lantheus Holdings' prostate cancer imaging agent, aimed at improving scanning access through...
Researchers at Spain's University of Granada have developed an artificial cornea made from the scales of several fish species commonly found in markets, which could become...
Activity restriction does not appear to lower the risk for preterm birth in pregnant women with a short cervix; it may even have the opposite effect.
The World Health Organization warned on Tuesday that the 'black rain' and toxic compounds in the air in Iran after strikes on oil facilities could cause respiratory problems.
A key U.S. federal vaccine advisory panel has dropped a push against COVID mRNA vaccines, the Washington Post reported on Wednesday, citing two people familiar with the...
In patients with COPD, starting the umeclidinium-vilanterol dry powder inhaler may lower the risk for exacerbations compared with starting glycopyrrolate-formoterol or tiotropium-olodaterol inhalers.
1.
'Chemo brain' cognitive issues linked to poor lymphatic-system drainage
2.
First-Line HCC Trial's Lenvatinib-Pembrolizumab Combo Misses Target.
3.
Anti-PD-L1 Plus Targeted Agent No Better Than Chemo for Resistant NSCLC
4.
Advanced Solid Tumors May Benefit from Investigative Immunotherapy Combo.
5.
For the treatment of paroxysmal nocturnal hemoglobinuria, the FDA has approved an oral factor B inhibitor.
1.
All You Need To Know About Partial Thromboplastin Time (PTT) Test
2.
Optimizing Cancer Care: Multidisciplinary Approaches and Supportive Strategies
3.
Multimodal Data Fusion with Deep Neural Networks - Revolutionizing Oncology with Precision Cancer Diagnosis 2025
4.
Gene Signatures and Their Implications in Oncology: Decoding the Blueprint for Personalized Cancer Treatment
5.
Breakthroughs in Cancer Care: From Rare Diagnoses to Advanced and Early-Stage Treatments
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
First Line Combination Therapy- The Overall Survival Data in NSCLC Patients
2.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part IV
3.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
4.
Evolving Space of First-Line Treatment for Urothelial Carcinoma- Case Discussion
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part I
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation